Healthcare entity
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention ADC Therapeutics, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention ADC Therapeutics, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.3 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention RAP-219, all published on March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RAP-219. Shared-story counts are live from our verified record — not editorial picks.
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics reported their full-year 2025 financial results on March 10, 2026, highlighting a period of clinical execution and capital management. The updates underscore the diverging paths of commercial-stage ADC platforms and late-stage cardiovascular and neuroscience pipelines as they navigate the 2026 regulatory landscape.
Source: manilatimes.net · manilatimes.net
RAP-219 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
